small molecule

NEURACEQ

FLORBETABEN F-18

Loss of exclusivityJuly 2032latest FDA-listed patent expiry
CompanyLANTHEUS BIOSCIENCES LTD

Drug detail

Brand nameNEURACEQ
Active ingredientFLORBETABEN F-18
Strength1.4-135mCi/ML
Dosage formSOLUTION
RouteINTRAVENOUS
ModalitySmall molecule
FDA approvalMarch 2014
Marketing statusRX

Listed patents

PatentExpiresType
9308284July 2032product
7807135March 2029substance, product

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

NEURACEQ patent cliff — loss of exclusivity July 2032 | CliffBio